https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-dreamm-7-head-to-head-phase-iii-trial-for-blenrep/
0
0
GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in relapsed/refractory multiple myeloma - GSK
11/27/23 at 7:09am
Organization
Gsk.com
Authors
Details
36 words
Summarize
Pharmaceuticals & Biotech Business & Industrial Drugs & Medications News DREAMM-7 GSK BorDex PFS Blenrep
Blenrep plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex.
Create an account or login to join the discussion